⚠️
Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Elevated cost per beneficiary
Risk indicators are statistical patterns, not allegations. Learn more
12,151
Total Claims
$6.2M
Drug Cost
1,228
Beneficiaries
$5,074
Cost/Patient
Risk Score Breakdown 3/100
Low (0)Moderate (15)Elevated (30)High (50+)
Cost per patient outlier+3
Score components are additive. Read full methodology
Peer Comparison vs. 6,382 Endocrinology providers
+29%
Cost per patient vs peers
$5,074 vs $3,933 avg
-10%
Brand preference vs peers
46.1% vs 51.2% avg
Brand vs Generic
54% generic
Brand: 5,331 claims · $5.9M
Generic: 6,234 claims · $202K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Semaglutide | 858 | $1.5M |
| Empagliflozin | 465 | $663K |
| Insulin Lispro | 225 | $309K |
| Dulaglutide | 133 | $285K |
| Dapagliflozin Propanediol | 228 | $284K |
| Sitagliptin Phosphate | 192 | $233K |
| Insulin Glargine,hum.Rec.Anlog | 227 | $208K |
| Liraglutide | 86 | $179K |
| Abaloparatide | 59 | $171K |
| Semaglutide | 81 | $165K |
| Insulin Degludec | 161 | $164K |
| Denosumab | 92 | $158K |
| Insulin Glargine,hum.Rec.Anlog | 112 | $143K |
| Insulin Lispro | 57 | $133K |
| Tirzepatide | 69 | $130K |
Prescribing Profile
Patient Profile
71
Avg Age
72%
Female
2.07
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About